5 Results for "

tepotinib

" in MedChemExpress (MCE) Product Catalog:
Products (5)

5 Results for "tepotinib" in MCE Product Catalog:

9
9 Cited Publications
Cat. No.: HY-14721
CAS No.: 1100598-32-0
Purity:  99.94%
Synonyms: EMD-1214063
Target:  

c-Met/HGFR Autophagy

Research Areas:  

Cancer

Tepotinib (EMD-1214063) is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC50 of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib inhibits c-Met phosphorylation and induces autophagy. Tepotinib has antitumor effects .
loading...
    loading...
Cat. No.: HY-14721R
CAS No.: 1100598-32-0
Synonyms: EMD-1214063 (Standard)
Research Areas:  

Cancer

Tepotinib (Standard) is the analytical standard of Tepotinib. This product is intended for research and analytical applications. Tepotinib (EMD-1214063) is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC50 of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib inhibits c-Met phosphorylation. Tepotinib has antitumor effects .
loading...
    loading...
Cat. No.: HY-14721A
CAS No.: 1103508-80-0
Synonyms: EMD-1214063 hydrochloride
Target:  

c-Met/HGFR Autophagy

Research Areas:  

Cancer

Tepotinib (EMD-1214063) hydrochloride is an orally active and highly selective, reversible, ATP-competitive c-Met inhibitor with an IC50 of 3 nM, >200-fold selective for c-Met than IRAK4, TrkA, Axl, IRAK1, and Mer. Tepotinib hydrochloride inhibits c-Met phosphorylation and induces autophagy. Tepotinib hydrochloride has antitumor effects .
loading...
    loading...
Cat. No.: HY-175320
Research Areas:  

Cancer

PROTAC c-Met degrader-5 is an orally active c-Met PROTAC degrader. PROTAC c-Met degrader-5 induces c-Met degradation via Cullin-CRBN, with a DC50 value of 0.32 nM, and inhibits the phosphorylation of c-Met and its downstream signaling molecule STAT3. PROTAC c-Met degrader-5 inhibits cancer cell proliferation, migration and invasion, induces apoptosis, alters cell cycle distribution, and suppresses the growth of EBC-1 xenograft tumors. PROTAC c-Met degrader-5 can be used to study MET-driven cancers as well as Tepotinib (HY-14721)-resistant cancers harboring c-Met D1228N and c-Met Y1230H mutations .
loading...
    loading...
Cat. No.: HY-162679
Target:  

c-Met/HGFR HyT

Research Areas:  

Cancer

c-Met degrader-1 is an orally active c-Met HyT degrader with a DC50 of 226.12 nM. c-Met degrader-1 exhibits anticancer activity against hepatocellular carcinoma. c-Met degrader-1 can be used in the research of hepatocellular carcinoma (HCC) (c-Met ligand: Tepotinib (HY-14721), hydrophobic tag moiety: Adamantan-1-ylmethanamine (HY-W037848)) .
loading...
    loading...